Genentech/Wellcome TPA suit
Executive SummaryGenentech says it won decisions in "all matters" of the tissue plasminogen activator patent and antitrust litigation with Burroughs Wellcome and Genetics Institute ("The Pink Sheet" March 12, T&G-4). In an April 6 jury decision in Wilmington, Delaware Federal Court, the jury found that "Wellcome and Genetics Institute infringed three Genentech TPA patents and upheld the validity and enforceability of those patents, but did not award any monetary damages," Genentech said. The jury also denied Wellcome's antitrust claims against Genentech as well as Genetics Institute's claim of unfair competition, according to Genentech. Genentech plans to file for a court injunction preventing Wellcome and Genetics Institute from marketing their first and second generation TPA products in the U.S.
You may also be interested in...
Hikma and Civica Rx have announced the launch of a first wave of eight essential injectable medicines, including heparin, as part of a deal struck between the two firms earlier this year.
A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.
Amneal has acquired a majority stake in manufacturer and wholesaler AvKARE, giving the firm access to the “large, complex and growing federal healthcare market.”